A drug company announced on Friday that eight lots of Irbesatan blood pressure medication have been recalled after testing showed the medication contained trace amounts of a cancer-causing material.
Specifically, one lot of Irbesartan tablets and seven lots of Irbesartan HCTZ tablets were recalled.
Prinstin Pharmaceuticals said the medication contained unacceptable levels of Nitrosodiethylamine -- or NDEA-- a likely carcinogen.
The ingredients were manufactured by Zheijiang Huahai Pharmaceuticals in China, a company which has been linked to several recalls of regularly-prescribed blood pressure drugs since July.
These are the lots that have been recalled, per the FDA:
| RBESARTAN TABLETS 300MG 90CT | 43547-376-09 | 331B18009 | 02/2021 | 8/9/2018 |
| IRBESARTAN/HCTZ 300MG/12.5MG 30CT TABLETS | 43547-331-03 | 327A18001 | 03/2021 | 7/10/2018 |
| IRBESARTAN/HCTZ 300MG/12.5MG 30 CT TABLETS | 43547-331-03 | 327A18002 | 03/2021 | 7/10/2018 |
| IRBESARTAN/HCTZ 300MG/12.5MG 90CT TABLETS | 43547-331-09 | 327B18008 | 03/2021 | 7/10/2018 |
| IRBESARTAN/HCTZ 300MG/12.5MG 90CT TABLETS | 43547-331-09 | 327B18009 | 03/2021 | 7/10/2018 |
| IRBESARTAN/HCTZ 150MG/12.5MG 30CT | 43547-330-03 | 325D18004 | 03/2021 | 7/10/2018 |
| IRBESARTAN/HCTZ 150MG/12.5MG 90CT TABLETS | 43547-330-09 | 325B18004 | 03/2021 | 8/24/2018 |
| IRBESARTAN/HCTZ 150MG/12.5MG 30CT TABLETS | 43547-330-03 | 325D18005 | 03/2021 | 7/10/2018 |
RELATED: New year, new blood pressure medication recall: Drug tablets recalled over cancer concern
